News

A new study by University of Kentucky Markey Cancer Center researchers shows that when therapy-sensitive cancer cells die, they release a "killer peptide" that can eliminate therapy-resistant cells.

Research Building 2 (RB2) is a precious resource and a vehicle for UK to reduce the health disparities that most impact Kentucky.

UK announces $11.2 million NIH grant for cancer and metabolism center that supports research by junior faculty.

John R. van Nagell, Jr. has worked with countless patients, faculty and students, but his lasting legacy will likely be the Ovarian Cancer Screening Program at the Markey Cancer Center.

Dr. John van Nagell spent his career at UK diagnosing and treating patients, and mentoring and teaching young doctors, but his lasting legacy will likely be his research.

A newly proposed clinical trial could change how deadly triple-negative breast cancer is treated.

Stamm's work shows the function of snoRNAs in regulating alternative splicing.

Doug Andres is exploring the link between RIT1 mutations and lung cancer.

Fifteen years ago Douglas Andres and his team produced data that showed mutations in an on-off switch called RIT1 are a novel driver for human lung cancer.

Jenna Hatcher is taking preventive health care into the emergency department, “because for many Kentuckians that’s where they find their medical home."